Nutriband (NASDAQ:NTRB – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Earnings and Valuation
This table compares Nutriband and Gyre Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutriband | $2.04 million | 33.30 | -$8.23 million | ($2.58) | -2.17 |
| Gyre Therapeutics | $116.59 million | 6.16 | $5.03 million | ($0.21) | -30.67 |
Risk & Volatility
Nutriband has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Nutriband and Gyre Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
Gyre Therapeutics has a consensus price target of $16.00, indicating a potential upside of 148.45%. Given Gyre Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Nutriband.
Institutional and Insider Ownership
19.7% of Nutriband shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Nutriband and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nutriband | -448.25% | -112.64% | -97.86% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Summary
Gyre Therapeutics beats Nutriband on 10 of the 14 factors compared between the two stocks.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
